TSX:IMV - Toronto Stock Exchange - CA44974L3011 - Common Stock - Currency: CAD
TSX:IMV (4/28/2023, 7:00:00 PM)
1.12
-0.02 (-1.75%)
The current stock price of IMV.CA is 1.12 CAD. In the past month the price increased by 55.56%. In the past year, price decreased by -92.91%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 261.54M | ||
EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 188.23M | ||
EDT.CA | SPECTRAL MEDICAL INC | N/A | 185.09M | ||
TH.CA | THERATECHNOLOGIES INC | N/A | 121.39M | ||
MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 89.95M | ||
ONC.CA | ONCOLYTICS BIOTECH INC | N/A | 82.42M | ||
MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 78.27M | ||
COV.CA | COVALON TECHNOLOGIES LTD | 25.45 | 76.72M | ||
MBX.CA | MICROBIX BIOSYSTEMS INC | 48.5 | 65.22M | ||
MDCX.CA | MEDICUS PHARMA LTD | N/A | 61.74M | ||
SVA.CA | SERNOVA BIOTHERAPEUTICS INC | N/A | 52.45M | ||
HBP.CA | HELIX BIOPHARMA CORP | N/A | 51.96M |
IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company is headquartered in Dartmouth, Nova Scotia and currently employs 63 full-time employees. The company went IPO on 2007-10-24. The firm is focused on developing a portfolio of therapies based on DPX, an immune-educating technology platform, that is designed to inform a specific anti-tumor immune response, offering benefit to patients with solid or hematological cancers. Its lead candidate, maveropepimut-S (MVP-S) is a DPX-based immunotherapy that targets survivin-expressing cells for elimination by educated, cytotoxic T cells. Its other candidates include DPX-RSV and DPX-COVID-19. DPX-RSV is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. The company is focused on developing DPX-COVID-19, a vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using its DPX platform. The firm is also developing maveropepimut-S for the treatment of breast and ovarian cancer, as well as for Diffuse large B-cell lymphoma (DLBCL) and other malignancies.
IMV Inc
130 Eileen Stubbs Ave Suite 19
Dartmouth NOVA SCOTIA B3B 2C4 CA
CEO: Frederic Ors
Employees: 63
Company Website: https://imv-inc.com/
Phone: 19024921819.0
The current stock price of IMV.CA is 1.12 CAD. The price decreased by -1.75% in the last trading session.
The exchange symbol of IMV Inc is IMV and it is listed on the Toronto Stock Exchange exchange.
IMV.CA stock is listed on the Toronto Stock Exchange exchange.
7 analysts have analysed IMV.CA and the average price target is 28.69 CAD. This implies a price increase of 2461.38% is expected in the next year compared to the current price of 1.12. Check the IMV Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
IMV Inc (IMV.CA) has a market capitalization of 13.12M CAD. This makes IMV.CA a Nano Cap stock.
IMV Inc (IMV.CA) currently has 63 employees.
IMV Inc (IMV.CA) has a support level at 0.71 and a resistance level at 1.25. Check the full technical report for a detailed analysis of IMV.CA support and resistance levels.
The Revenue of IMV Inc (IMV.CA) is expected to decline by -80.66% in the next year. Check the estimates tab for more information on the IMV.CA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
IMV.CA does not pay a dividend.
IMV Inc (IMV.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.19).
ChartMill assigns a technical rating of 2 / 10 to IMV.CA. When comparing the yearly performance of all stocks, IMV.CA is a bad performer in the overall market: 99.11% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to IMV.CA. IMV.CA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months IMV.CA reported a non-GAAP Earnings per Share(EPS) of -6.19. The EPS increased by 4.44% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 80% to IMV.CA. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 20.34% and a revenue growth -80.66% for IMV.CA